Robert D. Simpson
Boehringer Ingelheim
26 Papers
219 Citations
Robert D. Simpson is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Plasma renin activity & Renin–angiotensin system. The author has an hindex of 12, co-authored 26 publications.
Chat about Author
Papers
Patent
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
David A. Claremon,Colin M. Tice,Yuanjie Ye,Suresh B. Singh,Wei He,Wei Zhao,Robert D. Simpson +6 more
- 26 Feb 2009
TL;DR: In this paper, the authors proposed a novel compound of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSDl in mammals.
55
Patent
Lactam Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1
David A. Claremon,Linghang Zhuang,Yuanjie Ye,Suresh B. Singh,Colin M. Tice,Zhenrong Xu,Robert D. Simpson +6 more
- 07 Jan 2009
TL;DR: In this article, the authors proposed a method for the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol.
25
Development of a Pilot-Plant Process for a Nevirapine Analogue HIV NNRT Inhibitor
Carl A. Busacca,Mike Cerreta,Yong Dong,Magnus C. Eriksson,Vittorio Farina,XuWu Feng,Ji-Young Kim,Jon C. Lorenz,Max Sarvestani,Robert D. Simpson,Rich Varsolona,Jana Vitous,Scot J. Campbell,Mark S. Davis,Paul-James Jones,Daniel L. Norwood,Fenghe Qiu,Pierre L. Beaulieu,Jean-Simon Duceppe,Bruno Haché,Jim Brong,Fang-Ting Chiu,Tom Curtis,Jason Kelley,Young S. Lo,Tory H. Powner +25 more
TL;DR: In this paper, the pilot-plant synthesis of nevirapine analogue was described, which was prepared in eight steps from substituted pyridine raw materials and 4-hydroxyquinoline.
25
Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design
Colin M. Tice,Wei Zhao,Zhenrong Xu,Salvacion Cacatian,Robert D. Simpson,Yuanjie Ye,Suresh B. Singh,Brian M. McKeever,Peter Lindblom,Joan Guo,Paula Krosky,Barbara A. Kruk,Jennifer Berbaum,Richard K. Harrison,Judith J. Johnson,Yuri Bukhtiyarov,Reshma Panemangalore,Boyd B. Scott,Yi Zhao,Joseph G. Bruno,Linghang Zhuang,Gerard McGeehan,Wei He,David A. Claremon +23 more
TL;DR: Structure-guided drug design led to the identification of a class of spirocyclic ureas which potently inhibit human 11beta-HSD1 in vitro.
24
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
Colin M. Tice,Zhenrong Xu,Jing Yuan,Robert D. Simpson,Salvacion Cacatian,Patrick T. Flaherty,Wei Zhao,Joan Guo,Ishchenko Alexey,Suresh B. Singh,Zhongren Wu,Boyd B. Scott,Yuri Bukhtiyarov,Jennifer Berbaum,Jennifer M. Mason,Reshma Panemangalore,Maria Grazia Cappiello,Dominik N. Müller,Richard K. Harrison,Gerard McGeehan,Lawrence W. Dillard,Baldwin John J,David A. Claremon +22 more
TL;DR: Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension.
19